Related Experiment Video
Updated: May 25, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Endovascular renal artery denervation: why, when, and how?
Marc Sapoval1, Michel Azizi, Guillaume Bobrie
1Université Paris Descartes, Hôpital Europeen Georges Pompidou Radiologie Interventionnelle, Paris, France. marc.sapoval2@egp.aphp.fr
Endovascular renal artery denervation (ERAD) offers a new treatment for hypertension by reducing sympathetic overactivity. This catheter-based procedure shows promising results for drug-resistant cases.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
Background:
- Sympathetic overactivity is a recognized contributor to human hypertension.
- Experimental and human studies confirm the central role of sympathetic overactivity in hypertension.
Purpose of the Study:
- To elucidate the medical and technical aspects of endovascular renal artery denervation (ERAD).
- To provide guidance for interventionalists on this novel hypertension treatment.
Main Methods:
- Focus on radiofrequency-based endovascular renal artery denervation (ERAD).
- Review of findings from a cohort study and an open-label randomized control trial.
Main Results:
- Encouraging results reported from recent clinical trials.
- ERAD demonstrates potential as an adjunct therapy for resistant hypertension.
Conclusions:
- Endovascular renal artery denervation (ERAD) is a viable new procedure for managing hypertension.
- While other techniques may emerge, radiofrequency-based ERAD is the current available option.
Related Concept Videos
Imaging Studies VII: Vascular Imaging
Hemodialysis I: Introduction
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Continuous Renal Replacement Therapy
